Your fact-checks will appear here
Prescription obesity medications like tirzepatide and semaglutide have produced large, reproducible effects in clinical trials.
The name “” refers to conflicting products: an injectable prescription drug whose active ingredient is and a range of over‑the‑counter weight‑loss supplements sold under similar names that contain bot...
is prescribed as a once-weekly subcutaneous injection with an initial 2.5 mg starting dose (used for initiation only) that is generally titrated upward in 2.5 mg steps to maintenance doses of 5 mg, 10...
Real‑world observational studies of to date are short (median follow‑up well under two years) and heterogeneous, so there is effectively no robust real‑world evidence demonstrating cardiovascular outc...
is marketed as a natural dietary supplement whose label lists botanicals such as green tea extract, Gymnema sylvestre, and chromium picolinate among other components, but dietary supplements are not “...
The treats medicines and weight‑loss devices as fundamentally different regulatory products: most pharmaceutical obesity treatments are reviewed and approved through the drug new drug application (NDA...
User reports and clinical/postmarketing data converge on a clear pattern: gastrointestinal complaints — especially nausea, diarrhea, and vomiting — dominate ’s side-effect profile and are dose‑depende...
Tirzepatide is a dual GIP/GLP‑1 receptor agonist approved for type 2 diabetes and chronic weight management that shows substantial efficacy but carries a predictable cluster of adverse effects—primari...
Dual GIP/GLP‑1 agonists like tirzepatide reduce weight and improve multiple cardiometabolic risk factors that plausibly lower heart‑failure events in obese patients, particularly HFpEF, via hemodynami...
Systematic reviews find that most over‑the‑counter “fat‑burner” supplements produce little or no clinically meaningful weight loss, while a small set of nutraceuticals show modest, peer‑reviewed benef...